Who
Troy A. Ignelzi
Director
Company insider
Files Form 4 as: Director, Contineum Therapeutics; Director, Harmony Biosciences Holdings; Chief Financial Officer, Rapport Therapeutics; Chief Financial Officer, Karuna Therapeutics; Director, CinCor Pharma; Chief Financial Officer, scPharmaceuticals.
In numbers
- Trades disclosed
- 160
- Buys
- 2
- Sells
- 33
- Bought
- $101K
- Sold
- $25.8M
- Companies
- 6
- Companies where not an officer
- 3
- First trade
- 17 Jan 2018
- Last trade
- 26 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 26 Jun 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 26 Jun 2026filed 26 Jun 2026 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —17,710 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | HRMY Harmony Biosciences Holdingsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —17,710 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —148,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —148,000 at $0.00 | filing |
| 26 Jun 2025filed 26 Jun 2025 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,750 at $0.00 | filing |
| 13 Mar 2025filed 13 Mar 2025 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Bought | $998100 at $9.98 | filing |
| 12 Mar 2025filed 13 Mar 2025 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Bought | $100K9,900 at $10.10 | filing |
| 3 Feb 2025filed 4 Feb 2025 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —142,000 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —81,366 at $0.00 | filing |
| 24 May 2024filed 29 May 2024 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,350 at $0.00 | filing |
| 20 May 2024filed 20 May 2024 | CTNM Contineum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,150 at $0.00 | filing |
| 22 Aug 2023filed 24 Aug 2023 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code M | —1,500 at $0.00 | filing |
| 22 Aug 2023filed 24 Aug 2023 | Karuna Therapeutics | SEC FORM 4 Code M | $14K1,500 at $9.20 | filing |
| 22 Aug 2023filed 24 Aug 2023 | Karuna Therapeutics | SEC FORM 4 Sold | $14K80 at $173.64 | filing |
| 22 Aug 2023filed 24 Aug 2023 | Karuna Therapeutics | SEC FORM 4 Sold | $150K855 at $174.88 | filing |
| 22 Aug 2023filed 24 Aug 2023 | Karuna Therapeutics | SEC FORM 4 Sold | $89K505 at $175.59 | filing |
| 22 Aug 2023filed 24 Aug 2023 | Karuna Therapeutics | SEC FORM 4 Sold | $11K60 at $176.60 | filing |
| 23 May 2023filed 25 May 2023 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code M | —9,000 at $0.00 | filing |
News
Why Is Rapport Therapeutics Stock Trading Higher Today?RAPP · aol.com · 20 Oct 2026Rapport Therapeutics Rockets On Positive, But Mixed, Bipolar DataRAPP · investors.com · 20 Oct 2026Rapport Therapeutics (NASDAQ:RAPP) CEO Abraham Ceesay Sells 1,147 Shares of Company StockRAPP · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Troy A. Ignelzi; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.